tiprankstipranks
Trending News
More News >
ScandiDos AB (SE:SDOS)
:SDOS
Sweden Market

ScandiDos AB (SDOS) AI Stock Analysis

Compare
0 Followers

Top Page

SE:SDOS

ScandiDos AB

(SDOS)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 5.2)
Rating:50Neutral
Price Target:
kr0.98
▼(-14.61% Downside)
Action:N/ADate:01/04/26
The score is held back primarily by weak financial performance: recurring losses and negative, worsening free cash flow despite stable revenue. Support comes from a low-debt balance sheet that reduces financial distress risk and moderately improving near-term technical momentum, but valuation remains challenged due to loss-making results.
Positive Factors
Conservative balance sheet
Near-zero debt materially reduces solvency and refinancing risk over the coming months, giving management flexibility to fund operations, R&D or absorb timing mismatches without urgent external financing. That structural buffer improves resilience during loss-making periods.
Healthy gross margins
A ~55% gross margin indicates strong unit economics and pricing power in core QA products and software. If operating expenses are controlled, these margins can meaningfully improve operating profitability and support reinvestment in product development and service capabilities over the medium term.
Recurring revenue from installed base
Service, support and software maintenance create durable, contractable revenue streams that smooth sales cyclicality from hardware deals. An installed base with recurring spend increases customer lifetime value, provides cross-sell opportunities and underpins more predictable revenue over 2–6 months.
Negative Factors
Negative and deteriorating cash flow
Persistent negative operating and free cash flow erodes liquidity and forces reliance on external financing or equity raises. Over a multi-month horizon this constrains investments in sales, service and product development, increases funding risk and limits strategic optionality despite low debt.
Persistent losses and flat revenue
Flat-to-declining revenue alongside repeated negative EBIT and net losses signals structural challenges in scaling sales or controlling operating costs. Continued unprofitability reduces internal funding capacity and raises execution risk for reaching sustainable profitability within months.
Very small scale and earnings volatility
A tiny workforce limits commercial reach, service capacity and R&D scale versus larger medical device peers. Small scale magnifies the impact of lost deals and lengthens payback on investments, making revenue and margin improvements harder to achieve and maintain over the medium term.

ScandiDos AB (SDOS) vs. iShares MSCI Sweden ETF (EWD)

ScandiDos AB Business Overview & Revenue Model

Company DescriptionScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; and Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation. The company was founded in 2005 and is headquartered in Uppsala, Sweden.
How the Company Makes Money

ScandiDos AB Financial Statement Overview

Summary
Income statement performance is weak (flat-to-down revenue, negative EBIT and net loss), and cash flow is negative with deteriorating free cash flow, indicating ongoing cash burn. The main offset is a conservative balance sheet with essentially no debt, which lowers solvency risk but does not fix the underlying profitability issue.
Income Statement
34
Negative
TTM (Trailing-Twelve-Months) revenue is roughly flat to slightly down (about -2.5%), and profitability remains weak with a small net loss and negative EBIT, despite a healthy gross margin (~55%). The longer-term record shows volatile results: near break-even in 2021, then deeply negative profitability in 2022–2025 annual periods (large negative net margins), suggesting execution and cost-structure challenges even though gross profit margins were strong in prior annual reports.
Balance Sheet
72
Positive
The balance sheet is conservatively positioned with essentially no debt in recent periods (0 debt-to-equity in the latest reports), which reduces financial risk and provides flexibility. However, shareholder returns are negative (negative return on equity across periods), reflecting that the equity base is not currently generating profits; assets and equity have also moved around year-to-year, consistent with an uneven earnings profile.
Cash Flow
41
Neutral
Cash generation is inconsistent. TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are negative, and free cash flow deteriorated sharply versus the prior period, indicating higher cash burn. While some years showed positive operating cash flow (and even positive free cash flow in 2021), other years were meaningfully negative (notably 2023), highlighting volatility and limited self-funding capacity at the current profitability level.
BreakdownTTMApr 2024Apr 2023Apr 2023Apr 2021Apr 2021
Income Statement
Total Revenue59.49M60.43M60.43M61.55M57.68M59.99M
Gross Profit32.52M47.55M47.55M52.95M47.92M49.73M
EBITDA571.00K-5.79M-13.36M-8.26M-7.11M-1.58M
Net Income-1.38M-14.65M-14.65M-9.12M-7.34M-1.40M
Balance Sheet
Total Assets68.29M73.38M81.47M72.42M66.19M77.16M
Cash, Cash Equivalents and Short-Term Investments5.70M10.06M1.53M3.55M6.24M9.00M
Total Debt0.000.000.000.000.0083.00K
Total Liabilities25.09M28.40M37.19M30.77M28.99M31.98M
Stockholders Equity43.19M44.98M44.29M41.65M37.20M45.18M
Cash Flow
Free Cash Flow-1.72M-2.71M-1.46M-16.31M-2.31M4.08M
Operating Cash Flow-1.10M230.00K1.49M-11.90M2.39M8.64M
Investing Cash Flow-1.72M-2.94M-2.94M-4.37M-4.77M-4.63M
Financing Cash Flow0.000.000.0012.33M-83.00K-1.66M

ScandiDos AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
kr55.98M51.83
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SDOS
ScandiDos AB
0.97
-0.53
-35.60%
DE:LS60
Clinical Laserthermia Systems AB Class B
0.45
0.15
50.34%
DE:2OK
SpectraCure AB
0.01
-0.04
-80.00%
DE:24C
C-Rad AB Class B
2.31
-0.44
-16.00%
DE:LUR
Luxbright AB
0.03
-0.03
-51.67%
DE:MN2
Mentice AB
1.38
-0.56
-28.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026